Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP5 | Q13451 | 1/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.41 |
| ▸ | MMP3 | P08254 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 3/20 | 0.41 |
| ▸ | MMP8 | P22894 | 3/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.41 |
| ▸ | MME | P08473 | 9/20 | 0.40 |
| ▸ | ACE | P12821 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15134405 | 0.90 | MME (0.46) | MMEACEKDM4EPOLBECE1 | |
| SCHEMBL4903224 | 0.90 | MME (0.46) | MMEACEKDM4EPOLBECE1 | |
| SCHEMBL18576543 | 0.90 | MME (0.46) | MMEACEKDM4EPOLBECE1 | |
| SCHEMBL20367630 | 0.90 | MME (0.46) | MMEACEKDM4EPOLBECE1 | |
| SCHEMBL6501628 | 0.88 | MME (0.44) | MMEACEKDM4EPOLBECE1 | |
| SCHEMBL6814128 | 0.88 | MME (0.44) | MMEACEKDM4EPOLBECE1 | |
| SCHEMBL6813416 | 0.88 | MME (0.44) | MMEACEKDM4EPOLBECE1 | |
| Proline SCHEMBL4619772 | 0.84 | FKBP5 (0.52) | FKBP5CRBNOR51E2MMP1MMP2 | |
| Proline SCHEMBL195276 | 0.84 | FKBP5 (0.52) | FKBP5CRBNOR51E2MMP1MMP2 | |
| SCHEMBL14414157 | 0.83 | SLC6A1 (0.39) | FKBP5CRBNMMEACEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178541-A1 | BIOABSORBABLE ELASTOMERIC ARTERIAL SUPPORT DEVICE AND METHODS OF USE | Medivas, LLC (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2170355-A1 | BIOABSORBABLE ELASTOMERIC POLYMER NETWORKS, CROSS-LINKERS AND METHODS OF USE | Medivas, LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| US-7649022-B2 | Bioabsorbable elastomeric polymer networks, cross-linkers and methods of use | MEDIVAS, LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090253809-A1 | BIOABSORBABLE ELASTOMERIC POLYMER NETWORKS, CROSS-LINKERS AND METHODS OF USE | MEDIVAS, LLC (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2009011938-A1 | BIOABSORBABLE ELASTOMERIC ARTERIAL SUPPORT DEVICE AND METHODS OF USE | MEDIVAS, LLC (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20090022772-A1 | BIOABSORBABLE ELASTOMERIC ARTERIAL SUPPORT DEVICE AND METHODS OF USE | MEDIVAS, LLC (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2008121895-A1 | BIOABSORBABLE ELASTOMERIC POLYMER NETWORKS, CROSS-LINKERS AND METHODS OF USE | MEDIVAS, LLC (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253809-A1 | BIOABSORBABLE ELASTOMERIC POLYMER NETWORKS, CROSS-LINKERS AND METHODS OF USE | FAU, PEF1, APEH | FKBP5 86/4885CRBN 1931/4885OR51E2 4657/4885 |
| US-20090022772-A1 | BIOABSORBABLE ELASTOMERIC ARTERIAL SUPPORT DEVICE AND METHODS OF USE | BCAT1, VEGFA, ADM2 | FKBP5 490/4885CRBN 1565/4885OR51E2 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.